{"id":"NCT03433677","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes","officialTitle":"A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Patients With Type 1 Diabetes (PRONTO-Pump)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-21","primaryCompletion":"2018-09-04","completion":"2018-09-04","firstPosted":"2018-02-14","resultsPosted":"2019-10-08","lastUpdate":"2019-10-08"},"enrollment":49,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Type 1"],"interventions":[{"type":"DRUG","name":"LY900014","otherNames":["Ultra-Rapid Lispro"]},{"type":"DRUG","name":"Insulin lispro","otherNames":["Humalog"]}],"arms":[{"label":"LY900014","type":"EXPERIMENTAL"},{"label":"Insulin Lispro","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.","primaryOutcome":{"measure":"Rate of Infusion Set Failures","timeFrame":"6 Weeks","effectByArm":[{"arm":"Insulin Lispro (HumalogÂ®)","deltaMin":0.05,"sd":null},{"arm":"LY900014","deltaMin":0.03,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.375"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":5,"countries":["United States","Spain"]},"refs":{"pmids":[],"seeAlso":["https://www.lillytrialguide.com/en-US/studies/type-1-diabetes/ITSI#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":49},"commonTop":["Infusion site reaction","Infusion site pain"]}}